# Acknowledgements & Inspirations

---

### Regulatory Leadership & Vision

**FDA Center for Drug Evaluation and Research (CDER):**

- Draft guidance on AI in Drug Development (January 2025) provided the regulatory scaffolding for decision governance thinking
- Recognition of decision reconstructability challenges in FDAÂ 483 observations informed the core RGDS thesis
- Support for early regulatory engagement signaled openness to novel governance frameworks

**FDA Center for Biologics Evaluation and Research (CBER):**

- AI-enabled device software guidance informed the 7-step credibility framework integration with RGDS----

---

### Thought Leaders & Referenced Works

**Duke Margolis Institute for Health Policy:**

- December 2022 expert workshop on AI in drug development informed FDA's January 2025 guidance
- Referenced in multiple sources as foundational AI governance thinking

**International Organizations:**

- **WHO:** 2024 ethical guidelines on AI transparency, accessibility, validation, and monitoring
- **EMA:** 2024 pharmacovigilance AI integration guidance on transparency and governance
- **ICH:** Ongoing harmonization efforts informing global decision governance standards

---

### Industry Contributors

**Regulatory Consulting Firms:**

- Lumanity, McKinsey, Deloitte: Analysis of FDA trends and portfolio management ROI
- RAPS, FDLI: Professional organization perspectives on regulatory compliance and innovation

**Software Vendors:**

- Certara (eCTD expertise)
- Veeva, MasterControl (enterprise PM tools referenced)
- GitHub (decision log repository infrastructure)

**Biopharma/biotech Leaders:**

- Referenced case studies from public earnings calls and regulatory announcements
- Industry feedback on portfolio management, governance challenges, and competitive positioning

---

### Foundational Frameworks

**Project Management & Governance:**

- Kanbo, Planview: Portfolio and resource management methodologies
- RACI/DACI decision frameworks: Human review and approval chain structure

**Data Science & Machine Learning:**

- FDA's recognition of explainability and interpretability challenges informed AI governance disclosure sections
- SHAP values, saliency maps, and interpretability surrogate methods referenced as transparency tools

**Financial Analysis:**

- Analysis Group, Generate Capital: Biotech asset valuation and ROI quantification methodologies
- Portfolio-level NPV and probability-of-success modeling informed financial ROI calculations

---

---

## Document Version & Updates

- **Web edition:** MkDocs site build
- **Source:** `docs/index.md` derived from `RGDS_Whitepaper_Phase5_with_bibliography_REVIEW_COPY.md`
- **Last updated:** 2026-01-07
- **Change note:** Formatting normalized for web rendering (lists, notes, active links). Wording unchanged.

## How to Use These References

### For Regulatory Submissions:

- Cite FDA sources (ID-128, ID-131, ID-221, ID-227) as regulatory precedent for decision governance in FDA meetings
- Reference McKinsey, Deloitte, and Lumanity analyses to establish industry benchmarking data

### For Internal Communications:

- Use industry analysis sources (ID-196, ID-222, ID-225) for board presentations on regulatory trends
- Reference case studies from consultancy reports for business case development

### For Thought Leadership:

- Leverage academic sources (ID-211, ID-214, ID-216) for regulatory science publications
- Reference RAPS, FDLI, law firm analyses (ID-207, ID-209, ID-210, ID-217) for regulatory professional credibility

### For Implementation Planning:

- Use change management sources (ID-186, ID-188, ID-192, ID-203) for organizational rollout roadmaps
- Reference portfolio management sources (ID-182, ID-184) for portfolio-level program planning

---